The distribution of tumor-specific antigens, such as IL-13Rα2, Her2, and EGFRvIII, is heterogeneous in GB, and they are expressed to different degrees at different time points during CAR-T cell therapy87,95. This evidence concerns the gene IL13RA2 and neoplasm.